MuscleFreak
Well-known Member
https://joejefferycoaching.com/all-content/2020/5/3/dosing-gh-to-maximise-fat-loss
Growth Hormone & Insulin, Fat Loss
As a cliff note, this article will not be getting into the mechanisms by which rHGH promotes lipolysis, what environment to use GH in, what type of activity to pair your GH use with etc. In the spirit of keeping these articles practical and to the point, we will be discussing what dose to use to maximise fat loss only.
Luckily for us, we have clinical data that demonstrates the ceiling dose for topping out free fatty acid mobilisation from rHGH use. [1]
As with all drugs we use in bodybuilding, contrary to popular belief, more is not better. There are counter-regulatory mechanisms in place to prevent additional lipolysis from occurring at above a certain threshold.
So let’s cut to the chase, what is that dose?
The study measures the effects of no rHGH at all and 1mcg/kg, 3mcg/kg, and 6mcg/kg of rHGH on FFA mobilisation when administered IV (alongside a couple of other markers, not relevant to our interests here).
As you can see from the image below, there was a dose-dependent increase in FFA mobilisation from no rHGH, up to 3mcg/kg. However, no additional effect is seen from doubling the dose to 6mcg/kg.
Left, Serum concentration curves of FFAs (A), BOH (B), and glycerol (C) after iv infusions at t = 0 min of placebo (○) or GH at doses of 1 μg/kg−1 (•), 3 μg/kg−1 (▵), and 6 μg/kg−1 (▴). Right, The integrated response was assessed as iAUC0–300 min. Data are means ± SE, n = 18. *P < 0.05 and **P < 0.01, compared with placebo; †, P < 0.05, compared with 1 μg/kg−1 GH.
If you are a 100kg male, that means per dose of rHGH, 300mcg would be your ceiling to maximise the lipolytic effect.
1000mcg = 3iu, so 300mcg = around about 1iu.
Now, remember that this study was measured using an IV administration, which I would recommend to absolutely nobody. The risk of infection is bad enough with the repeat exposure that bodybuilders see, let alone a venous infection, which is devastating.
From a paper comparing the bioavailability of IV vs sub-q administration: “Higher mean integrated values (AUC) of serum GH (mU/l) were obtained with i.v. GH delivery [47.4 +/- 5.1 (i.v.), 33.3 +/- 3.0 (s.c.), P < 0.05].” [2]
33.3/47.4 = 0.7
Thus, we see a comparative bioavailability of 70% with sub-q as compared to IV.
Accounting for the lesser bioavailability of a sub-q administration, we are left with a 1.3iu sub-q dose.
So there we have it, the maximum effective dose of rHGH for fat loss is 1.3iu/100kg bodyweight.
Simply divide 1.3 by 100 and multiply by your bodyweight in kilos if you want to see where your individual accurate dosing lies.
[1] Troels Krarup Hansen, Claus Højbjerg Gravholt, Hans Ørskov, Michael Højby Rasmussen, Jens Sandahl Christiansen, Jens Otto L. Jørgensen, Dose Dependency of the Pharmacokinetics and Acute Lipolytic Actions of Growth Hormone, The Journal of Clinical Endocrinology & Metabolism, Volume 87, Issue 10, 1 October 2002, Pages 4691–4698, Dose Dependency of the Pharmacokinetics and Acute Lipolytic Actions of Growth Hormone
[2] Laursen T, Møller J, Jørgensen JO, Orskov H, Christiansen JS. Bioavailability and bioactivity of intravenous vs subcutaneous infusion of growth hormone in GH-deficient patients. Clin Endocrinol (Oxf). 1996;45(3):333‐339. doi:10.1046/j.1365-2265.1996.00814.x
Growth Hormone & Insulin, Fat Loss
As a cliff note, this article will not be getting into the mechanisms by which rHGH promotes lipolysis, what environment to use GH in, what type of activity to pair your GH use with etc. In the spirit of keeping these articles practical and to the point, we will be discussing what dose to use to maximise fat loss only.
Luckily for us, we have clinical data that demonstrates the ceiling dose for topping out free fatty acid mobilisation from rHGH use. [1]
As with all drugs we use in bodybuilding, contrary to popular belief, more is not better. There are counter-regulatory mechanisms in place to prevent additional lipolysis from occurring at above a certain threshold.
So let’s cut to the chase, what is that dose?
The study measures the effects of no rHGH at all and 1mcg/kg, 3mcg/kg, and 6mcg/kg of rHGH on FFA mobilisation when administered IV (alongside a couple of other markers, not relevant to our interests here).
As you can see from the image below, there was a dose-dependent increase in FFA mobilisation from no rHGH, up to 3mcg/kg. However, no additional effect is seen from doubling the dose to 6mcg/kg.
Left, Serum concentration curves of FFAs (A), BOH (B), and glycerol (C) after iv infusions at t = 0 min of placebo (○) or GH at doses of 1 μg/kg−1 (•), 3 μg/kg−1 (▵), and 6 μg/kg−1 (▴). Right, The integrated response was assessed as iAUC0–300 min. Data are means ± SE, n = 18. *P < 0.05 and **P < 0.01, compared with placebo; †, P < 0.05, compared with 1 μg/kg−1 GH.
If you are a 100kg male, that means per dose of rHGH, 300mcg would be your ceiling to maximise the lipolytic effect.
1000mcg = 3iu, so 300mcg = around about 1iu.
Now, remember that this study was measured using an IV administration, which I would recommend to absolutely nobody. The risk of infection is bad enough with the repeat exposure that bodybuilders see, let alone a venous infection, which is devastating.
From a paper comparing the bioavailability of IV vs sub-q administration: “Higher mean integrated values (AUC) of serum GH (mU/l) were obtained with i.v. GH delivery [47.4 +/- 5.1 (i.v.), 33.3 +/- 3.0 (s.c.), P < 0.05].” [2]
33.3/47.4 = 0.7
Thus, we see a comparative bioavailability of 70% with sub-q as compared to IV.
Accounting for the lesser bioavailability of a sub-q administration, we are left with a 1.3iu sub-q dose.
So there we have it, the maximum effective dose of rHGH for fat loss is 1.3iu/100kg bodyweight.
Simply divide 1.3 by 100 and multiply by your bodyweight in kilos if you want to see where your individual accurate dosing lies.
[1] Troels Krarup Hansen, Claus Højbjerg Gravholt, Hans Ørskov, Michael Højby Rasmussen, Jens Sandahl Christiansen, Jens Otto L. Jørgensen, Dose Dependency of the Pharmacokinetics and Acute Lipolytic Actions of Growth Hormone, The Journal of Clinical Endocrinology & Metabolism, Volume 87, Issue 10, 1 October 2002, Pages 4691–4698, Dose Dependency of the Pharmacokinetics and Acute Lipolytic Actions of Growth Hormone
[2] Laursen T, Møller J, Jørgensen JO, Orskov H, Christiansen JS. Bioavailability and bioactivity of intravenous vs subcutaneous infusion of growth hormone in GH-deficient patients. Clin Endocrinol (Oxf). 1996;45(3):333‐339. doi:10.1046/j.1365-2265.1996.00814.x
